Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults
about
Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)A review of malaria vaccine clinical projects based on the WHO rainbow tableNeutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewA glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primatesRecombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine DevelopmentPhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsHuman vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.The influence of delivery vectors on HIV vaccine efficacySterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesRandomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responsesDNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum EpitopesControlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malariaPre-erythrocytic malaria vaccines: identifying the targets.Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNAProgress and prospects for blood-stage malaria vaccinesIdentification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsImmunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vecHuman adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Development of replication-deficient adenovirus malaria vaccines.A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage ChallengeHuman CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice.Cellular immune response to DNA and vaccinia prime-boost immunization kills Plasmodium yoelii-infected hepatocytes in vitro.Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
P2860
Q21034050-1ECADB22-0BB7-4E02-BBD8-641075E78160Q21034112-1FD17C86-7031-4184-9845-BE5F8BB0416BQ26700078-208C1479-B01A-4B99-946A-A4ADF6A2157DQ27303293-F4FE3AD7-51E1-430F-8FB8-2D2A9D7568AFQ27321063-FFBDDCF6-FBE6-4E53-B1C3-723797A6207DQ27972709-595E1345-225F-4926-9C99-A520F0CC2967Q28731894-AC3EE9A2-6318-4719-B492-D920C5025BE3Q33798074-6571C95B-2D2B-4CBB-BA98-D4FE62EAC334Q34077543-9DFBB689-0635-46CD-9CD7-2ABD203B1C5BQ34165879-53291E70-58CF-47BE-B63F-2B4E5487EEBDQ34170122-806D51F7-7238-4E44-82B7-0CB4464CC2F7Q34229968-C900EBDF-B1B5-4FF2-8B3E-21B147ECA4C7Q34606356-2BC382E4-3454-43D8-9491-314A33A99479Q34734075-9624714C-BCA6-4984-A711-C583DC7687B8Q35021277-403CCAE3-3580-49C5-9DBB-52909D046606Q35079832-4C1F30A4-AB1C-4701-8F25-512C58572FB9Q36151198-5AE1C45F-A841-4DE4-AD70-B493552CFDF8Q36389006-DBA382EB-ABB9-4FF2-AD38-4027B3CC9BDEQ36394177-E78A4329-22B3-4226-9A52-13BB0D19AC50Q36460499-EC59B611-F147-4A50-A705-702C4407E21FQ36531046-FFF11F8E-442D-4A74-86DA-096027F2B365Q36644236-E94F3BDF-755D-48D5-9080-51C50968E8B1Q36674446-71096521-7F8A-46AB-BE0C-693D96F06B2AQ36694820-BFD2EEB1-C1B7-4C2C-AA9E-788C57D95AB0Q37025030-0CCA06F8-CF8A-4409-95D2-C9E59FB948BDQ37123522-D34AEFA8-E0E3-422E-9865-0F76A13E19F6Q37218080-11E58F4D-7E48-4C27-869E-A436F573677AQ37264651-35CEDB81-67D1-43FD-B127-F19E277AD05BQ37285734-AE8250DF-644B-4000-92F0-2208FE6CE2CFQ37530505-53B4BA07-7DF9-40CC-878F-BC12FD10F0CAQ37546314-C25644D8-DB41-44BC-8F26-C4CFF50FB0D2Q38096489-50B9A861-7FA3-44D8-8DD0-5D252BD0867BQ38096490-EFA2A287-5E6B-4452-8070-540768E652D4Q38949194-1C20B535-551F-4E1D-92EA-AC4F3C667E06Q39315273-97FFC91B-1CDC-456B-B5F0-4273A58C393FQ39510998-8F10C97F-A086-439E-A8BF-D6C327446485Q40213640-3A9E8507-3B35-4B1F-B820-49A3A366C8C4Q47576664-83A85898-B85D-40F4-88F3-9247BE556DC3Q47993724-9E20FEA8-95CA-44E2-A8E6-841ADD20995B
P2860
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@ast
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@en
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@nl
type
label
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@ast
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@en
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@nl
prefLabel
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@ast
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@en
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@nl
P2093
P2860
P50
P3181
P1433
P1476
Adenovirus 5-vectored P. falci ...... enicity in seronegative adults
@en
P2093
Brent House
C Richter King
Carter Diggs
Chloe Wood
Christian F Ockenhouse
Cindy Tamminga
Daniel Carucci
David Regis
Denise L Doolan
Esteban Abot
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0024586
P407
P577
2011-01-01T00:00:00Z